PHARMACEUTICAL FORMULATIONS COMPRISING ANTI-CORONAVIRUS S PROTEIN ANTIBODIES AND USES THEREOF
The present disclosure is directed to pharmaceutical formulations comprising antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S). Other embodiments of the disclosure include the use of pharmaceutical formulations for the diagnosis,...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | MANNING, Mark DABORA, Rebecca HOLCOLM, Ryan RATNASWAMY, Gayathri MARTIN-MOE, Sheryl |
| description | The present disclosure is directed to pharmaceutical formulations comprising antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S). Other embodiments of the disclosure include the use of pharmaceutical formulations for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and/or prophylactically beneficial.
La présente invention concerne des formulations pharmaceutiques comprenant des anticorps, et des fragments de liaison à l'antigène de ceux-ci, ayant une spécificité de liaison pour la protéine S des coronavirus (CoV-S). D'autres modes de réalisation de la divulgation comprennent l'utilisation de formulations pour le diagnostic, l'évaluation et le traitement de maladies et de troubles associés à des coronavirus, ou à la protéine S correspondante, et des conditions dans lesquelles la neutralisation ou l'inhibition des coronavirus, ou de la protéine S correspondante, serait bénéfique sur le plan thérapeutique et/ou prophylactique. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023059900A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023059900A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023059900A23</originalsourceid><addsrcrecordid>eNqNirEKwjAUALM4iPoPAedCaHHo-ExT86DJKy-JTlKKxEm0UP8fi_gBTndwtxbX3gI70CZF1NDJltilDiKSD1KT6xkD-pMEH7HQxOThjJyCDLJnigb9Nx2pQRMWbWQKi0Rr2FC7Fav7-Jjz7seN2Lcmalvk6TXkeRpv-Znfw4VKVVbqUNdKQVn9d30AEVY0HQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PHARMACEUTICAL FORMULATIONS COMPRISING ANTI-CORONAVIRUS S PROTEIN ANTIBODIES AND USES THEREOF</title><source>esp@cenet</source><creator>MANNING, Mark ; DABORA, Rebecca ; HOLCOLM, Ryan ; RATNASWAMY, Gayathri ; MARTIN-MOE, Sheryl</creator><creatorcontrib>MANNING, Mark ; DABORA, Rebecca ; HOLCOLM, Ryan ; RATNASWAMY, Gayathri ; MARTIN-MOE, Sheryl</creatorcontrib><description>The present disclosure is directed to pharmaceutical formulations comprising antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S). Other embodiments of the disclosure include the use of pharmaceutical formulations for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and/or prophylactically beneficial.
La présente invention concerne des formulations pharmaceutiques comprenant des anticorps, et des fragments de liaison à l'antigène de ceux-ci, ayant une spécificité de liaison pour la protéine S des coronavirus (CoV-S). D'autres modes de réalisation de la divulgation comprennent l'utilisation de formulations pour le diagnostic, l'évaluation et le traitement de maladies et de troubles associés à des coronavirus, ou à la protéine S correspondante, et des conditions dans lesquelles la neutralisation ou l'inhibition des coronavirus, ou de la protéine S correspondante, serait bénéfique sur le plan thérapeutique et/ou prophylactique.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230413&DB=EPODOC&CC=WO&NR=2023059900A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230413&DB=EPODOC&CC=WO&NR=2023059900A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MANNING, Mark</creatorcontrib><creatorcontrib>DABORA, Rebecca</creatorcontrib><creatorcontrib>HOLCOLM, Ryan</creatorcontrib><creatorcontrib>RATNASWAMY, Gayathri</creatorcontrib><creatorcontrib>MARTIN-MOE, Sheryl</creatorcontrib><title>PHARMACEUTICAL FORMULATIONS COMPRISING ANTI-CORONAVIRUS S PROTEIN ANTIBODIES AND USES THEREOF</title><description>The present disclosure is directed to pharmaceutical formulations comprising antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S). Other embodiments of the disclosure include the use of pharmaceutical formulations for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and/or prophylactically beneficial.
La présente invention concerne des formulations pharmaceutiques comprenant des anticorps, et des fragments de liaison à l'antigène de ceux-ci, ayant une spécificité de liaison pour la protéine S des coronavirus (CoV-S). D'autres modes de réalisation de la divulgation comprennent l'utilisation de formulations pour le diagnostic, l'évaluation et le traitement de maladies et de troubles associés à des coronavirus, ou à la protéine S correspondante, et des conditions dans lesquelles la neutralisation ou l'inhibition des coronavirus, ou de la protéine S correspondante, serait bénéfique sur le plan thérapeutique et/ou prophylactique.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNirEKwjAUALM4iPoPAedCaHHo-ExT86DJKy-JTlKKxEm0UP8fi_gBTndwtxbX3gI70CZF1NDJltilDiKSD1KT6xkD-pMEH7HQxOThjJyCDLJnigb9Nx2pQRMWbWQKi0Rr2FC7Fav7-Jjz7seN2Lcmalvk6TXkeRpv-Znfw4VKVVbqUNdKQVn9d30AEVY0HQ</recordid><startdate>20230413</startdate><enddate>20230413</enddate><creator>MANNING, Mark</creator><creator>DABORA, Rebecca</creator><creator>HOLCOLM, Ryan</creator><creator>RATNASWAMY, Gayathri</creator><creator>MARTIN-MOE, Sheryl</creator><scope>EVB</scope></search><sort><creationdate>20230413</creationdate><title>PHARMACEUTICAL FORMULATIONS COMPRISING ANTI-CORONAVIRUS S PROTEIN ANTIBODIES AND USES THEREOF</title><author>MANNING, Mark ; DABORA, Rebecca ; HOLCOLM, Ryan ; RATNASWAMY, Gayathri ; MARTIN-MOE, Sheryl</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023059900A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>MANNING, Mark</creatorcontrib><creatorcontrib>DABORA, Rebecca</creatorcontrib><creatorcontrib>HOLCOLM, Ryan</creatorcontrib><creatorcontrib>RATNASWAMY, Gayathri</creatorcontrib><creatorcontrib>MARTIN-MOE, Sheryl</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MANNING, Mark</au><au>DABORA, Rebecca</au><au>HOLCOLM, Ryan</au><au>RATNASWAMY, Gayathri</au><au>MARTIN-MOE, Sheryl</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PHARMACEUTICAL FORMULATIONS COMPRISING ANTI-CORONAVIRUS S PROTEIN ANTIBODIES AND USES THEREOF</title><date>2023-04-13</date><risdate>2023</risdate><abstract>The present disclosure is directed to pharmaceutical formulations comprising antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S). Other embodiments of the disclosure include the use of pharmaceutical formulations for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and/or prophylactically beneficial.
La présente invention concerne des formulations pharmaceutiques comprenant des anticorps, et des fragments de liaison à l'antigène de ceux-ci, ayant une spécificité de liaison pour la protéine S des coronavirus (CoV-S). D'autres modes de réalisation de la divulgation comprennent l'utilisation de formulations pour le diagnostic, l'évaluation et le traitement de maladies et de troubles associés à des coronavirus, ou à la protéine S correspondante, et des conditions dans lesquelles la neutralisation ou l'inhibition des coronavirus, ou de la protéine S correspondante, serait bénéfique sur le plan thérapeutique et/ou prophylactique.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2023059900A2 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | PHARMACEUTICAL FORMULATIONS COMPRISING ANTI-CORONAVIRUS S PROTEIN ANTIBODIES AND USES THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T20%3A27%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MANNING,%20Mark&rft.date=2023-04-13&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023059900A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |